Erasca, Inc. (ERAS) Stock Price & Analysis

Erasca, Inc. (ERAS) rose 4.20% to USD 13.41 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.

ERAS last closed at USD 12.87; the session ranged USD 12.26–13.44 on volume of 4,475,440 shares. Market capitalization is $4.17B, with a 52-week range of USD 1.21–24.28 (NMS). Source: Nexqual, June 10, 2026 at 02:21 UTC.

Key Statistics (as of June 10, 2026 at 02:21 UTC)

Technical Analysis (ERAS)

Nexqual's technical model rates ERAS "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:21 UTC.

Analyst Ratings (ERAS)

Wall Street analysts rate ERAS "Buy" based on 10 analysts, with a mean price target of USD 21 (range USD 12–30), per Nexqual as of June 10, 2026 at 02:21 UTC.

Earnings (ERAS)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financials & Fundamentals (ERAS)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financial Health Score (ERAS)

Nexqual rates Erasca, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:21 UTC.

Ownership (ERAS)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Leadership (ERAS)

Erasca, Inc. is led by Jonathan E. Lim (age 53), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 02:21 UTC.

Major Backers & Investors (ERAS)

Notable institutional backers of Erasca, Inc. include T. Rowe Price, Frazier Life Sciences Management, L.P. , Venrock Adviser, LLC, according to Nexqual as of June 10, 2026 at 02:21 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:21 UTC.

From Erasca, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Jonathan Lim, our Chairman, CEO, and Co-Founder, has helped pioneer transformative advancements in precision oncology and drug delivery, including leading Ignyta's trailblazing pursuit of a global tissue agnostic label for ROZLYTREK, which became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA).
• Our pipeline enables us to pursue a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs.
• Our modality-agnostic approach aims to allow us to selectively and potently target critical signaling nodes with the most appropriate modality, including small and large molecule therapeutics.
• Following this review, in order to prioritize organizational focus and resources to advance our differentiated RAS-targeting franchise, we decided to evaluate strategic alternatives for our naporafenib program, which we in-licensed from Novartis Pharma AG (Novartis).

Partnerships

• In March 2026, we sent a notice to Novartis to terminate our exclusive license agreement with Novartis (as amended, the Novartis Agreement) pursuant to which we acquired exclusive rights to develop naporafenib.
• We are pursuing tissue agnostic and tissue specific indications using flexible trial designs intended to efficiently transition molecules through each phase of development with the goal of identifying early efficacy signals warranting additional resource allocation for both monotherapy and combination approaches. 8   • Evaluate opportunities to accelerate development timelines and enhance the commercial potential of our programs in collaboration with third parties .

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.